Related Experiment Videos
[Antimicrobial activity of cefteram comparison with other oral antibiotics]
Abstract:
Antimicrobacterial activities of cefteram (CFTM) against clinical isolates collected in 1988 were compared with those of new beta-lactams. 1. Antibacterial activities of CFTM against Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, Branhamella catarrhalis isolated from acute respiratory tract infections were 8- to 16-fold higher than those of cefaclor (CCL). 2. Activities of cefixime (CFIX) were superior to those of CFTM against B. catarrhalis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, but were inferior to CFTM against S. pneumoniae, S. pyogenes, Staphylococcus saprophyticus and Staphylococcus aureus. 3. Activities of cefuroxime were superior to those of CCL against each of the 4 tested bacterial species from acute respiratory tract infection and S. aureus by 4-fold, but were inferior to CFTM and CFIX against most of Gram-negative rods. 4. Sultamicillin (SBTPC) is considered to have an activity to inhibit beta-lactamase, but its MICs did not exceed the MICs of ampicillin by itself. SBTPC showed poor antibacterial activities against methicillin-resistant S. aureus (MRSA). Considering these observations, it is apparent that we are faced with a variety of factors in selecting antibiotics for best results.
Insights
Cefteram (CFTM) exhibits potent antibacterial activity against respiratory pathogens, outperforming cefaclor (CCL). However, cefixime (CFIX) and cefuroxime show varied efficacy against different bacteria, necessitating careful antibiotic selection.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Antibiotic resistance is a growing concern, necessitating the evaluation of new antimicrobial agents.
- Beta-lactam antibiotics are crucial in treating bacterial infections, but their efficacy can be limited by resistance mechanisms.
Purpose of the Study:
- To compare the in vitro antibacterial activities of cefteram (CFTM) with other beta-lactam antibiotics against clinical isolates.
- To evaluate the efficacy of CFTM against common respiratory tract pathogens.
Main Methods:
- In vitro susceptibility testing was performed using minimum inhibitory concentration (MIC) assays.
- Clinical isolates from 1988 were used to assess the activity of CFTM, cefaclor (CCL), cefixime (CFIX), cefuroxime, and sultamicillin (SBTPC).
Main Results:
- CFTM demonstrated 8- to 16-fold higher activity than CCL against Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Branhamella catarrhalis.
- CFIX showed superior activity against B. catarrhalis, Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, but was less effective than CFTM against S. pneumoniae, S. pyogenes, Staphylococcus saprophyticus, and Staphylococcus aureus.
- Cefuroxime was more potent than CCL but less effective than CFTM and CFIX against most Gram-negative rods. SBTPC exhibited poor activity against methicillin-resistant S. aureus (MRSA).
Conclusions:
- Antibiotic selection requires careful consideration of the specific pathogen and its susceptibility profile.
- CFTM shows promising activity against key respiratory pathogens, offering a potential alternative to existing therapies.
- The comparative efficacy of different beta-lactams highlights the need for ongoing surveillance and tailored treatment strategies.